REGENXBIO (RGNX) Projected to Post Quarterly Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Wednesday, May 14th. Analysts expect REGENXBIO to post earnings of $0.35 per share and revenue of $105.35 million for the quarter.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The business had revenue of $21.21 million for the quarter, compared to analysts' expectations of $23.70 million. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

REGENXBIO Price Performance

RGNX stock opened at $7.92 on Wednesday. The firm has a 50-day moving average of $7.25 and a 200 day moving average of $8.06. The company has a market cap of $396.93 million, a P/E ratio of -1.57 and a beta of 1.11. REGENXBIO has a 1 year low of $5.04 and a 1 year high of $17.35.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. Morgan Stanley boosted their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, March 14th. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. HC Wainwright lowered their target price on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. Finally, Raymond James started coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an "outperform" rating and a $27.00 target price for the company. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.